Pliant Therapeutics Files 8-K on Executive Changes & Exit Costs
Ticker: PLRX · Form: 8-K · Filed: May 1, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, restructuring, disclosure
TL;DR
Pliant Therapeutics making moves: executive changes and exit costs reported.
AI Summary
Pliant Therapeutics, Inc. filed an 8-K on May 1, 2025, reporting on cost-associated exit or disposal activities and changes in directors or officers. The filing also details compensatory arrangements for certain officers, indicating potential restructuring or executive transitions within the company.
Why It Matters
This filing signals potential strategic shifts or financial restructuring at Pliant Therapeutics, which could impact its operational focus and future growth prospects.
Risk Assessment
Risk Level: medium — Changes in directors/officers and exit costs can indicate underlying business challenges or significant strategic realignments.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- May 1, 2025 (date) — Date of earliest event reported
- 331 Oyster Point Boulevard (location) — Business and Mail Address
- South San Francisco, CA (location) — Business and Mail Address City/State
- 94080 (location) — Business and Mail Address Zip Code
FAQ
What specific exit or disposal activities are being reported by Pliant Therapeutics?
The filing indicates 'Cost Associated with Exit or Disposal Activities' as an item of disclosure, but the specific details of these activities are not provided in the provided text.
Are there any changes to Pliant Therapeutics' board of directors or executive officers?
Yes, the filing explicitly lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of disclosure.
What is the nature of the compensatory arrangements being disclosed?
The filing mentions 'Compensatory Arrangements of Certain Officers,' suggesting details about executive compensation will be provided, though the specifics are not in the excerpt.
When was this 8-K filing submitted?
The filing was submitted as of May 1, 2025.
What is Pliant Therapeutics' state of incorporation and fiscal year end?
Pliant Therapeutics, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 regarding PLIANT THERAPEUTICS, INC. (PLRX).